Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to people familiar with the matter.
The Wall Street Journal reported earlier this month that Merck aimed to agree on a purchase of the cancer biotech within a few weeks, a plan that has since been delayed, the people said.
